Q2 Earnings Estimate for Novartis Issued By Zacks Research

Novartis AG (NYSE:NVS - Free Report) - Zacks Research issued their Q2 2025 earnings per share estimates for shares of Novartis in a research report issued on Tuesday, June 24th. Zacks Research analyst E. Bagri forecasts that the company will earn $2.34 per share for the quarter. The consensus estimate for Novartis' current full-year earnings is $8.45 per share. Zacks Research also issued estimates for Novartis' FY2025 earnings at $8.92 EPS and Q3 2026 earnings at $2.25 EPS.

Separately, BNP Paribas raised shares of Novartis to a "strong-buy" rating in a report on Tuesday, April 15th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $123.38.

Novartis Stock Up 2.0%

Shares of NYSE:NVS opened at $120.36 on Friday. The company's fifty day moving average is $113.76 and its 200-day moving average is $107.94. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.61 and a current ratio of 0.79. Novartis has a 52 week low of $96.06 and a 52 week high of $121.69. The company has a market capitalization of $254.24 billion, a PE ratio of 18.81, a P/E/G ratio of 1.70 and a beta of 0.59.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $2.28 earnings per share for the quarter, beating analysts' consensus estimates of $2.12 by $0.16. The firm had revenue of $13.23 billion for the quarter, compared to analysts' expectations of $12.92 billion. Novartis had a return on equity of 39.44% and a net margin of 24.70%. The business's revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.80 earnings per share.

Institutional Investors Weigh In On Novartis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NVS. Dimensional Fund Advisors LP increased its holdings in shares of Novartis by 5.2% in the first quarter. Dimensional Fund Advisors LP now owns 8,606,724 shares of the company's stock valued at $959,535,000 after purchasing an additional 422,869 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Novartis by 60.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,660,485 shares of the company's stock valued at $408,071,000 after buying an additional 1,377,252 shares during the last quarter. Renaissance Technologies LLC boosted its position in Novartis by 16.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,668,849 shares of the company's stock valued at $259,706,000 after buying an additional 368,171 shares during the last quarter. Northern Trust Corp increased its stake in shares of Novartis by 2.2% in the 1st quarter. Northern Trust Corp now owns 2,180,281 shares of the company's stock valued at $243,058,000 after buying an additional 47,690 shares during the period. Finally, Fisher Asset Management LLC raised its position in shares of Novartis by 17.4% during the fourth quarter. Fisher Asset Management LLC now owns 2,002,959 shares of the company's stock worth $194,908,000 after acquiring an additional 296,950 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company's stock.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.